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Introduction
Smoothened inhibitors have recently emerged as a nonsurgical,
targeted therapy for treating advanced basal cell carcinomas
(BCC) [8]. This novel small-molecule drug class suppresses
Hedgehog pathway signaling by binding the membrane pro-
tein, Smoothened [7, 9]. Dysregulation of Hedgehog signaling
is a hallmark of BCCs and is thought to play an integral role in
maintaining cancer growth [1]. Treatment of locally advanced
and metastatic basal cell carcinomas with the Smoothened
inhibitor vismodegib demonstrated a 40–50 % response rate
in Phase I and II trials, paving the way for FDA approval in
early 2012 [10]. This therapy is most useful in patients for
whom surgical resection is difficult or contraindicated due to
tumor size, location, recurrence after surgery, or co-morbid
medical conditions. Here, we report a case of a 43-year-old
man with numerous and large BCCs of the hand that led to
significant disability. The extent of disease suggested that sur-
gical treatment might result in unacceptable functional results.
There was involvement of a significant portion of the surface of
the hand, and surgical excision would have created a large soft
tissue defect requiring skin grafting, with the potential for scar
formation, contractures with limitation of motion, and poor
aesthetic outcome. Management with oral vismodegib resulted
in dramatic tumor regression, with good functional and aes-
thetic results.
Case Report
A 43-year-old Caucasian man with a known history of genetic
predisposition to BCC presented withmultiple large ulcerated,
biopsy proven BCCs on his head, trunk, arms, and legs [2]. In
particular, he noted the inability to type on a keyboard, drive a
car, or carry out activities of daily living due to the large BCCs
studding his dorsal hands, including some that traversed the
joints. He had a 2.5-cm multilobular BCC on the distal tip of
the left small finger (Fig. 1a).
After a discussion of his treatment options, the patient elected
to begin therapy with oral vismodegib 150 mg daily, due to the
size and extent of his tumors. After 1 month, shrinkage of all of
the BCCs was apparent (Fig. 1b). After 6 months of treatment,
the BCCs had regressed further, with the lesion on the distal fifth
digit receding the slowest (Fig. 1c). Continued treatment led to
further BCC shrinkage (Fig. 1d). Due to his vismodegib treat-
ment, he regained the ability to carry out activities of daily living,
with good functional and aesthetic results.While there are visible
scars in areas of previous BCC, the patient reported no limitation
in hand movement. In addition, several areas of erosion and
erythema were persistent at 3 years and 4 months of follow-up,
including the web space between the third and fourth digits,
suggesting that a small amount of residual BCCs remained.
However, the patient declined biopsy in the absence of lesion
growth. He continues to be monitored with full body skin
examinations every month for BCC chemoresistance.
Over the course of treatment, the patient experienced com-
monly reported side effects, including hair loss and mild mus-
cle cramping in the legs. He did not require treatment for his
muscle cramping. Otherwise, the drug was well tolerated.
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In conclusion, we present this case to illustrate the utility of a
new targeted therapy, oral Smoothened inhibitor treatment, for
BCCs of the hand that are not amenable to surgical resection.
While surgical excision of the majority of small BCCs is
highly effective, with 2- to 5-year recurrence rates of under
5 % for margins of 2–5 mm [3], patients with multifocal,
extensive and/or large tumors may not be good candidates
for surgical treatment. Although other treatment modalities
such as radiotherapy may be considered for these complex
cases, there are still long-term risks for secondary cancers and
scarring [4–6].
Currently, the response rate of advanced BCCs of the hand
compared to those of other anatomic locations is not known.
In the largest study of vismodegib for BCCs published to date,
a phase II clinical trial, the independently reviewed objective
response rate for locally advanced BCCs were 43 % [8], and
included BCCs of various anatomic locations.
We highlight three noteworthy aspects of the clinical man-
agement in this case. First, definitive diagnosis of the tumor by
histopathology is essential prior to initiation of Smoothened
inhibitor therapy, since other cutaneous malignancies such as
squamous carcinomas have not been reported to be dependent
on the Hedgehog signaling pathway [11]. Second, tumor
shrinkage can be apparent early in the treatment course. Our
patient's BCCs visibly decreased in size within 1 month of
starting vismodegib but did not achieve maximal regression
until 3 years of drug usage. Third, Smoothened inhibitor treat-
ment can produce durable results without significant scarring or
functional sequelae that might occur after surgical treatment.
Further studies are under way to assess the use of
Smoothened inhibitors to shrink BCCs preoperatively and/or
in combination with other treatment modalities. In cases
where Smoothened inhibitors alone fail to cure the disease
or to arrest tumor growth, improved outcomes may be
achieved with concomitant surgery or radiation therapy.
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Fig. 1 a Bulky BCC tumors on dorsal hands and fingers prior to
treatment with vismodegib. b After 4 weeks of vismodegib therapy,
shrinkage of the BCCs was clinically evident. c After 6 months of
vismodegib therapy, the BCCs continued to regress. d After 3 years of
vismodegib therapy, the BCCs were nearly eradicated without surgery. a
has previously been published in Gomez-Ospina et al [2]
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